Answers are grounded in this paper and cite their sources.
Background and objective This study focused on the economic evaluation of the step-up diagnostic strategy (transbronchial cryobiopsy followed by surgical lung biopsy (SLB) when needed) compared with the immediate SLB strategy (immediate SLB) for diagnosing interstitial lung disease (ILD). Methods A cost–utility analysis was conducted from both a healthcare and a societal perspective. The societal perspective extended the healthcare perspective by including productivity losses and patient out-of-pocket expenses. This study was performed alongside a randomised controlled trial in which patients were randomised to the step-up strategy or the immediate SLB strategy, with a time horizon of 12 weeks. The primary outcome was the cost per quality-adjusted life-year (QALY). Costs were addressed irrespective of payer source and included healthcare costs by providers, costs of productivity loss by employers and disease-related out-of-pocket expenses by patients. Results 47 patients were included: 25 patients in the step-up diagnostic strategy group and 22 in the immediate SLB strategy group. A mean difference of 0.025 (96% confidence interval (CI) 0.004–0.047; p=0.04) QALYs was found in favour of the step-up strategy. The cost per patient from the healthcare perspective was €4644 (95% CI €3683–€5803) for the step-up strategy group and €8935 (95% CI €8019–€9979) for the immediate SLB group. From a societal perspective, the cost was €6873 (95% CI €5014–€9113) in the step-up strategy group versus €12 924 (95% CI €10 745–€15 325) in the immediate SLB group. Conclusion The step-up diagnostic strategy is a cost-effective strategy for patients undergoing lung tissue acquisition for diagnosing ILD; therefore, implementation of this strategy is recommended.
No takes yet. Share an insight, caveat, or question.
Kalverda et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: